Follow the Sino Biopharmaceutical Ltd. share price and the full insider trade history of the company, a listed equity based in Hong Kong. Shares are listed on HK HK, under the supervision of HKEX. Operating in the Health Care sector, Sino Biopharmaceutical Ltd. has logged 6 reports. Market capitalisation: €93.1bn. The latest transaction was disclosed on 30 April 2026 (Purchase). Among the most active insiders: Cheng Cheung Ling. All data is accessible without an account.
Analysts rate Sino Biopharmaceutical Ltd. Strong Buy (bullish), based on 20 analysts. Average price target: HK$8.59.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
6 of 6 declarations
Sino Biopharmaceutical Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products in China. It primarily focuses on drugs for the treatment of liver diseases and cardiovascular diseases.